Abivax SA entered into an Underwriting Agreement on June 30, 2026, to issue and sell 6,400,000 American Depositary Shares at $125.00 per ADS. The company expects to receive approximately $759.8 million in net proceeds from the public offering. Abivax SA is a biotechnology company focused on developing therapies for inflammatory diseases.
